<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400033</url>
  </required_header>
  <id_info>
    <org_study_id>204837</org_study_id>
    <secondary_id>2017-004372-56</secondary_id>
    <nct_id>NCT03400033</nct_id>
  </id_info>
  <brief_title>Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy&#xD;
      and safety of daprodustat administered three-times weekly compared to epoetin alfa, the&#xD;
      current standard of care. This study includes a 4 week Screening Period, a 52 week Treatment&#xD;
      Period and a 4 to 6 week follow-up period. Each subject will remain in the study for up to 62&#xD;
      weeks. Approximately 402 subjects will be randomized to receive either daprodustat three&#xD;
      times weekly or epoetin alfa three-times weekly or once weekly, depending on dose level.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">June 19, 2020</completion_date>
  <primary_completion_date type="Actual">June 19, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive either daprodustat or epoetin alfa in a parallel manner. .</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double-blind study, in which the subject, investigator, site staff and the sponsor will remain blinded to each subjects study treatment assignment throughout the course of the study, with the exception of a limited number of unblinded site staff who are necessary to maintain the blind, as well as a limited number of sponsor staff.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)</time_frame>
    <description>Blood samples were collected from participants for hemoglobin measurements. Hemoglobin during the evaluation period was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Analysis was performed using the Analysis of Covariance (ANCOVA) model with terms for treatment, Baseline hemoglobin, and region.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant</measure>
    <time_frame>Day 1 to Week 52</time_frame>
    <description>Average monthly IV iron dose (mg) per participant during Day 1 to Week 52 was determined by calculating the total IV iron dose per participant from Day 1 to Week 52 while the participant was on study treatment and dividing by (the number of days the participant was on study treatment divided by 30.4375 days). Analysis was performed using the ANCOVA model with terms for treatment, Baseline monthly IV iron dose, and region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin Levels at Week 52</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and Week 52</time_frame>
    <description>Blood samples were collected from participants for hemoglobin measurements. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the post-randomization visit value minus Baseline value. Analysis was performed using a mixed model repeated measures (MMRM) model fitted to hemoglobin data collected after Baseline up to Week 52, excluding values collected during the stabilization period (Day 1 to Week 28). The model included factors for treatment, time, region, Baseline hemoglobin and Baseline hemoglobin by time and treatment by time interaction terms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)</measure>
    <time_frame>Week 28 to Week 52</time_frame>
    <description>Participants received treatment during the study to achieve or maintain hemoglobin level in the target range. Percentage of time for which hemoglobin level was maintained within the analysis range (10 to 11.5 grams/deciliter) has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)</measure>
    <time_frame>Week 28 to Week 52</time_frame>
    <description>Mean hemoglobin during the evaluation period was defined as the mean of all evaluable hemoglobin values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled hemoglobin values that were taken during this time period. Hemoglobin responders were defined as the number of participants with a mean hemoglobin during the evaluation period that falls within the hemoglobin analysis range of 10-11.5 grams/deciliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants permanently stopping study treatment due to meeting rescue criteria has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52</measure>
    <time_frame>Baseline (Week -4 ) and Week 52</time_frame>
    <description>Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model with treatment group, time, region, Baseline value, Baseline value*time, treatment group*time as variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SBP, DBP and MAP at End of Treatment</measure>
    <time_frame>Baseline (Week -4) and end of treatment (last on-treatment value until Week 52)</time_frame>
    <description>Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the last on-treatment visit value minus Baseline value. Analysis was performed using ANCOVA model with terms for treatment group, region and Baseline value. Adjusted mean and standard error have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>BP exacerbation event is defined (based on post-dialysis BP) as SBP &gt;=25 mmHg increased from Baseline or SBP &gt;=180 mmHg; or DBP &gt;=15 mmHg increased from Baseline or DBP &gt;=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One BP Exacerbation Event During the Study</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>BP exacerbation (based on post-dialysis BP) is defined as: SBP &gt;= 25 mmHg increased from Baseline or SBP &gt;=180mmHg; or DBP &gt;=15 mmHg increase from Baseline or DBP &gt;=110 mmHg. Number of participants with at least 1 BP exacerbation event have been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Weeks 8, 12, 28 and 52 in Patient Global Impression of Severity (PGI-S)</measure>
    <time_frame>Baseline (Pre-dose on Day 1) and Weeks 8, 12, 28, 52</time_frame>
    <description>The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity of their anemia of Chronic kidney disease (CKD). It is measured on a 5-point disease severity scale ranging from 0 (absent) to 4 (very severe), higher score indicates more disease severity. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline in on-treatment PGI-S scores was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model fitted from Baseline up to Week 52 with factors for treatment, time, region, Baseline value and Baseline value by time and treatment by time interactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Trough Concentration (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)</measure>
    <time_frame>Pre-dose on Day 1; Pre-dose and at 0.5, 1, 2, 3 hours post-dose on any one post-Baseline visit day between Week 8 and Week 52</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)</measure>
    <time_frame>Pre-dose on Day 1; Pre-dose and at 0.5, 1, 2, 3 hours post-dose on any one post-Baseline visit day between Week 8 and Week 52</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">407</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Daprodustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daprodustat tablets</intervention_name>
    <description>Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.</description>
    <arm_group_label>Daprodustat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo tablets</intervention_name>
    <description>Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa vials</intervention_name>
    <description>Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline vials or bags</intervention_name>
    <description>0.9% sodium chloride saline vials or bags administered by the IV route.</description>
    <arm_group_label>Daprodustat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be 18 to 99 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Use of any approved rhEPO or analog for at least 8 weeks prior to the screening visit&#xD;
             and continuing during the screening period until randomization (Day 1).&#xD;
&#xD;
          -  Hgb concentration (measured by HemoCue) within the following range: Week -4: Hgb 8 to&#xD;
             11.5 grams/deciliter (5 to 7.1 millimoles/liter). If Hgb is 11.6 to 11.9&#xD;
             grams/deciliter (7.2 to 7.4 millimoles/liter), up to two retests are allowed; the&#xD;
             retest value must be between 8 to 11.5 grams/deciliter (5 to 7.1 millimoles/liter).&#xD;
             Day 1: Hgb 8 to 11 grams/deciliter (5 to 6.8 millimoles/liter) and receiving at least&#xD;
             the minimum rhEPO or analog dose 3. Hgb&gt;11 to 11.5 grams/deciliter (6.8 to 7.1&#xD;
             millimoles/liter) and receiving greater than the minimum rhEPO or analog dose 3.&#xD;
&#xD;
          -  On hemodialysis (including hemofiltration or hemodiafiltration) &gt;90 days prior to&#xD;
             screening and continuing during the screening period.&#xD;
&#xD;
          -  On hemodialysis (in-center) &gt;=3 times per week.&#xD;
&#xD;
          -  Male and female subjects are eligible. A female subject is eligible to participate if&#xD;
             she is not pregnant, not breastfeeding, and at least one of the following conditions&#xD;
             applies: Not a woman of childbearing potential (WOCBP), or A WOCBP who agrees to&#xD;
             follow the contraceptive guidance from at least 28 days prior to first dose of study&#xD;
             treatment and for at least 28 days after the last dose of study treatment.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
          -  In France, a subject will be eligible for inclusion in this study if he or she is&#xD;
             either affiliated to or beneficiary of a social security category.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned living-related or living-unrelated kidney transplant within 52 weeks after&#xD;
             randomization (Day 1).&#xD;
&#xD;
          -  Ferritin: &lt;=100 nanograms/milliliter (&lt;=100 micrograms/liter), at screening.&#xD;
&#xD;
          -  Transferrin saturation (TSAT): &lt;=20 percent, at screening. If TSAT is 18 to 20&#xD;
             percent, then a retest using a new blood sample can be obtained within 7 days of the&#xD;
             final laboratory report; the final retest value must be &gt;20 percent to confirm&#xD;
             eligibility.&#xD;
&#xD;
          -  Aplasias: History of bone marrow aplasia or pure red cell aplasia.&#xD;
&#xD;
          -  Conditions, other than anemia of CKD, which can affect erythropoiesis.&#xD;
&#xD;
          -  Myocardial infarction (MI) or acute coronary syndrome within 8 weeks prior to&#xD;
             screening through to randomization (Day 1).&#xD;
&#xD;
          -  Stroke or transient ischemic attack within 8 weeks prior to screening through to&#xD;
             randomization (Day 1).&#xD;
&#xD;
          -  Heart failure (HF): Chronic Class IV HF, as defined by the New York Heart Association&#xD;
             (NYHA) functional classification system.&#xD;
&#xD;
          -  Current uncontrolled hypertension as determined by the investigator that would&#xD;
             contraindicate the use of rhEPO.&#xD;
&#xD;
          -  Bazett's correction of QTc interval (QTcB): at Day 1: QTcB &gt;500 milliseconds, or QTcB&#xD;
             &gt;530 milliseconds in subjects with bundle branch block. There is no QTc (corrected QT)&#xD;
             exclusion for subjects with a predominantly ventricular paced rhythm.&#xD;
&#xD;
          -  Liver Disease: presence of any one of the following liver-related laboratory values or&#xD;
             conditions, at screening, is exclusionary: ALT &gt;2x upper limit of normal (ULN);&#xD;
             Bilirubin &gt;1.5x ULN; or Current unstable liver or biliary disease per investigator&#xD;
             assessment, generally defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or&#xD;
             cirrhosis.&#xD;
&#xD;
          -  Evidence of actively bleeding gastric, duodenal or esophageal ulcer disease OR&#xD;
             clinically significant gastro intestinal bleeding &lt;= 8 weeks prior to screening&#xD;
             through to randomization (Day 1).&#xD;
&#xD;
          -  History of malignancy within 2 years prior to screening through to randomization (Day&#xD;
             1), currently receiving treatment for cancer, or complex kidney cyst (e.g., Bosniak&#xD;
             Category IIF, III or IV) &gt;3 centimeters.&#xD;
&#xD;
          -  Use of a strong inhibitor of Cytochrome P4502C8 [CYP2C8] (e.g. gemfibrozil) or a&#xD;
             strong inducer of CYP2C8 (e.g. rifampin/rifampicin).&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions or hypersensitivity to excipients&#xD;
             in the investigational product (daprodustat) or epoetin alfa.&#xD;
&#xD;
          -  Use of another investigational agent within 30 days or within five half-lives of the&#xD;
             investigational agent (whichever is longer) or currently participating in a study of&#xD;
             an investigational device prior to screening through to randomization (Day 1).&#xD;
&#xD;
          -  Any prior treatment with daprodustat for treatment duration of &gt;30 days.&#xD;
&#xD;
          -  Any other condition, clinical or laboratory abnormality, or examination finding that&#xD;
             the investigator considers would put the subject at unacceptable risk, which may&#xD;
             affect study compliance (e.g. intolerance to rhEPO) or prevent understanding of the&#xD;
             aims or investigational procedures or possible consequences of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>College Point</city>
        <state>New York</state>
        <zip>11356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pergamino</city>
        <state>Buenos Aires</state>
        <zip>B2700CPM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarandi</city>
        <state>Buenos Aires</state>
        <zip>B1872EEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40415-065</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80440-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande Do Sul</state>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte, Minas Gerais</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Epagny Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice Cedex 1</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anyang-Si, Gyeonggi-do</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goyang-si, Gyeonggi-do</city>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sandomierz</city>
        <zip>27-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarnowskie Gory</city>
        <zip>42-612</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zyrardow</city>
        <zip>96-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Resita</city>
        <zip>320166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolomna</city>
        <zip>140407</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnogorsk</city>
        <zip>143400</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mytischi</city>
        <zip>141009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novorossiysk</city>
        <zip>353915</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omsk</city>
        <zip>644111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orenburg</city>
        <zip>460040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Penza</city>
        <zip>440034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Podolsk</city>
        <zip>142110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193318</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ufa</city>
        <zip>450071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Granollers, Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manises (Valencia)</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sanlúcar De Barrameda (Cádiz)</city>
        <zip>11540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD5 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <results_first_submitted>June 18, 2021</results_first_submitted>
  <results_first_submitted_qc>June 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2021</results_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD, EPO, rhEPO, Hemodialysis dependent, Daprodustat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03400033/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03400033/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a multicenter study conducted at 90 centers in 13 countries. Participants were randomized to receive either Daprodustat or Epoetin alfa.</recruitment_details>
      <pre_assignment_details>A total of 595 participants were screened, of which 188 were screen failures. A total of 407 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Daprodustat</title>
          <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa</title>
          <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daprodustat</title>
          <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa</title>
          <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="270"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="407"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>19-64 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 65 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>BLACK OR AFRICAN AMERICAN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AMERICAN INDIAN OR ALASKAN NATIVE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIAN - CENTRAL/SOUTH ASIAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIAN - EAST ASIAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIAN - SOUTH EAST ASIAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHITE - ARABIC/NORTH AFRICAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MIXED WHITE RACE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MIXED RACE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>UNKNOWN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52)</title>
        <description>Blood samples were collected from participants for hemoglobin measurements. Hemoglobin during the evaluation period was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Analysis was performed using the Analysis of Covariance (ANCOVA) model with terms for treatment, Baseline hemoglobin, and region.</description>
        <time_frame>Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)</time_frame>
        <population>All Randomized (Intent-to-treat [ITT]) Population comprised of all randomized participants. Any participant who received a treatment randomization number was considered to have been randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52)</title>
          <description>Blood samples were collected from participants for hemoglobin measurements. Hemoglobin during the evaluation period was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Analysis was performed using the Analysis of Covariance (ANCOVA) model with terms for treatment, Baseline hemoglobin, and region.</description>
          <population>All Randomized (Intent-to-treat [ITT]) Population comprised of all randomized participants. Any participant who received a treatment randomization number was considered to have been randomized.</population>
          <units>Grams per deciliter (g/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.045"/>
                    <measurement group_id="O2" value="0.02" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be established if the lower limit of the two-sided 95 percent (%) confidence interval (CI) for the treatment difference is greater than the pre-specified non-inferiority margin of -0.75 g/dL.</non_inferiority_desc>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant</title>
        <description>Average monthly IV iron dose (mg) per participant during Day 1 to Week 52 was determined by calculating the total IV iron dose per participant from Day 1 to Week 52 while the participant was on study treatment and dividing by (the number of days the participant was on study treatment divided by 30.4375 days). Analysis was performed using the ANCOVA model with terms for treatment, Baseline monthly IV iron dose, and region.</description>
        <time_frame>Day 1 to Week 52</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant</title>
          <description>Average monthly IV iron dose (mg) per participant during Day 1 to Week 52 was determined by calculating the total IV iron dose per participant from Day 1 to Week 52 while the participant was on study treatment and dividing by (the number of days the participant was on study treatment divided by 30.4375 days). Analysis was performed using the ANCOVA model with terms for treatment, Baseline monthly IV iron dose, and region.</description>
          <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Milligrams</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.11" spread="11.049"/>
                    <measurement group_id="O2" value="106.23" spread="15.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3354</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-8.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.66</ci_lower_limit>
            <ci_upper_limit>29.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin Levels at Week 52</title>
        <description>Blood samples were collected from participants for hemoglobin measurements. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the post-randomization visit value minus Baseline value. Analysis was performed using a mixed model repeated measures (MMRM) model fitted to hemoglobin data collected after Baseline up to Week 52, excluding values collected during the stabilization period (Day 1 to Week 28). The model included factors for treatment, time, region, Baseline hemoglobin and Baseline hemoglobin by time and treatment by time interaction terms.</description>
        <time_frame>Baseline (Pre-dose on Day 1) and Week 52</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Levels at Week 52</title>
          <description>Blood samples were collected from participants for hemoglobin measurements. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the post-randomization visit value minus Baseline value. Analysis was performed using a mixed model repeated measures (MMRM) model fitted to hemoglobin data collected after Baseline up to Week 52, excluding values collected during the stabilization period (Day 1 to Week 28). The model included factors for treatment, time, region, Baseline hemoglobin and Baseline hemoglobin by time and treatment by time interaction terms.</description>
          <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Grams per deciliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.069"/>
                    <measurement group_id="O2" value="0.11" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be established if the lower limit of the two-sided 95% CI for the treatment difference is greater than the pre-specified non-inferiority margin of -0.75 g/dL.</non_inferiority_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)</title>
        <description>Participants received treatment during the study to achieve or maintain hemoglobin level in the target range. Percentage of time for which hemoglobin level was maintained within the analysis range (10 to 11.5 grams/deciliter) has been presented.</description>
        <time_frame>Week 28 to Week 52</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with at least one evaluable hemoglobin value during the evaluation period were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)</title>
          <description>Participants received treatment during the study to achieve or maintain hemoglobin level in the target range. Percentage of time for which hemoglobin level was maintained within the analysis range (10 to 11.5 grams/deciliter) has been presented.</description>
          <population>All Randomized (ITT) Population. Only those participants with at least one evaluable hemoglobin value during the evaluation period were analyzed.</population>
          <units>Percentage of days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.83" lower_limit="50.98" upper_limit="91.07"/>
                    <measurement group_id="O2" value="61.76" lower_limit="29.69" upper_limit="85.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be established if the lower limit of the two-sided 95% CI for the treatment difference was above the non-inferiority margin of - 15%.</non_inferiority_desc>
            <p_value>0.0034</p_value>
            <method>Van Elteren's test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>11.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.83</ci_lower_limit>
            <ci_upper_limit>19.56</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann Estimate of Treatment Difference has been reported.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)</title>
        <description>Mean hemoglobin during the evaluation period was defined as the mean of all evaluable hemoglobin values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled hemoglobin values that were taken during this time period. Hemoglobin responders were defined as the number of participants with a mean hemoglobin during the evaluation period that falls within the hemoglobin analysis range of 10-11.5 grams/deciliter.</description>
        <time_frame>Week 28 to Week 52</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with at least one evaluable hemoglobin value during the evaluation period were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)</title>
          <description>Mean hemoglobin during the evaluation period was defined as the mean of all evaluable hemoglobin values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled hemoglobin values that were taken during this time period. Hemoglobin responders were defined as the number of participants with a mean hemoglobin during the evaluation period that falls within the hemoglobin analysis range of 10-11.5 grams/deciliter.</description>
          <population>All Randomized (ITT) Population. Only those participants with at least one evaluable hemoglobin value during the evaluation period were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rate</param_type>
            <param_value>0.1645</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria</title>
        <description>Percentage of participants permanently stopping study treatment due to meeting rescue criteria has been presented.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>All Randomized (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria</title>
          <description>Percentage of participants permanently stopping study treatment due to meeting rescue criteria has been presented.</description>
          <population>All Randomized (ITT) Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5308</p_value>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>4.22</ci_upper_limit>
            <estimate_desc>Hazard ratio is estimated using a Cox proportional hazard regression model adjusted for treatment group and region.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52</title>
        <description>Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model with treatment group, time, region, Baseline value, Baseline value*time, treatment group*time as variables.</description>
        <time_frame>Baseline (Week -4 ) and Week 52</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52</title>
          <description>Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model with treatment group, time, region, Baseline value, Baseline value*time, treatment group*time as variables.</description>
          <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Millimeter of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="1.470"/>
                    <measurement group_id="O2" value="0.55" spread="2.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" spread="0.764"/>
                    <measurement group_id="O2" value="-0.29" spread="1.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="0.907"/>
                    <measurement group_id="O2" value="-0.12" spread="1.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>-3.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.03</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>SBP</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>-2.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.99</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
            <estimate_desc>DBP</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>-2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.86</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>MAP</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SBP, DBP and MAP at End of Treatment</title>
        <description>Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the last on-treatment visit value minus Baseline value. Analysis was performed using ANCOVA model with terms for treatment group, region and Baseline value. Adjusted mean and standard error have been presented.</description>
        <time_frame>Baseline (Week -4) and end of treatment (last on-treatment value until Week 52)</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP, DBP and MAP at End of Treatment</title>
          <description>Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the last on-treatment visit value minus Baseline value. Analysis was performed using ANCOVA model with terms for treatment group, region and Baseline value. Adjusted mean and standard error have been presented.</description>
          <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.24"/>
                    <measurement group_id="O2" value="-0.9" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.66"/>
                    <measurement group_id="O2" value="-0.8" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.78"/>
                    <measurement group_id="O2" value="-0.8" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.407</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.73</ci_lower_limit>
            <ci_upper_limit>3.72</ci_upper_limit>
            <estimate_desc>SBP</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.29</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>DBP</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.261</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.50</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
            <estimate_desc>MAP</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years</title>
        <description>BP exacerbation event is defined (based on post-dialysis BP) as SBP &gt;=25 mmHg increased from Baseline or SBP &gt;=180 mmHg; or DBP &gt;=15 mmHg increased from Baseline or DBP &gt;=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years</title>
          <description>BP exacerbation event is defined (based on post-dialysis BP) as SBP &gt;=25 mmHg increased from Baseline or SBP &gt;=180 mmHg; or DBP &gt;=15 mmHg increased from Baseline or DBP &gt;=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model.</description>
          <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Events per 100 participant years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.45" lower_limit="210.69" upper_limit="297.72"/>
                    <measurement group_id="O2" value="356.91" lower_limit="280.95" upper_limit="453.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>Negative binomial model</method>
            <param_type>Ratio of exacerbation rate</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One BP Exacerbation Event During the Study</title>
        <description>BP exacerbation (based on post-dialysis BP) is defined as: SBP &gt;= 25 mmHg increased from Baseline or SBP &gt;=180mmHg; or DBP &gt;=15 mmHg increase from Baseline or DBP &gt;=110 mmHg. Number of participants with at least 1 BP exacerbation event have been reported.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One BP Exacerbation Event During the Study</title>
          <description>BP exacerbation (based on post-dialysis BP) is defined as: SBP &gt;= 25 mmHg increased from Baseline or SBP &gt;=180mmHg; or DBP &gt;=15 mmHg increase from Baseline or DBP &gt;=110 mmHg. Number of participants with at least 1 BP exacerbation event have been reported.</description>
          <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Weeks 8, 12, 28 and 52 in Patient Global Impression of Severity (PGI-S)</title>
        <description>The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity of their anemia of Chronic kidney disease (CKD). It is measured on a 5-point disease severity scale ranging from 0 (absent) to 4 (very severe), higher score indicates more disease severity. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline in on-treatment PGI-S scores was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model fitted from Baseline up to Week 52 with factors for treatment, time, region, Baseline value and Baseline value by time and treatment by time interactions.</description>
        <time_frame>Baseline (Pre-dose on Day 1) and Weeks 8, 12, 28, 52</time_frame>
        <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed (represented as n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat</title>
            <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Weeks 8, 12, 28 and 52 in Patient Global Impression of Severity (PGI-S)</title>
          <description>The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity of their anemia of Chronic kidney disease (CKD). It is measured on a 5-point disease severity scale ranging from 0 (absent) to 4 (very severe), higher score indicates more disease severity. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline in on-treatment PGI-S scores was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model fitted from Baseline up to Week 52 with factors for treatment, time, region, Baseline value and Baseline value by time and treatment by time interactions.</description>
          <population>All Randomized (ITT) Population. Only those participants with data available at specified time points were analyzed (represented as n=X in the category titles).</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8; n=248, 126</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.048"/>
                    <measurement group_id="O2" value="0.05" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=243, 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.050"/>
                    <measurement group_id="O2" value="-0.01" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28; n=211, 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.054"/>
                    <measurement group_id="O2" value="0.03" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52; n=170, 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.063"/>
                    <measurement group_id="O2" value="0.04" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0323</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>Week 8</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0921</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>Week 12</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1291</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Week 28</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0859</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>Week 52</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Trough Concentration (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13).</description>
        <time_frame>Pre-dose on Day 1; Pre-dose and at 0.5, 1, 2, 3 hours post-dose on any one post-Baseline visit day between Week 8 and Week 52</time_frame>
        <population>Pharmacokinetic Population comprised of all randomized participants for whom a post-Baseline pharmacokinetic sample was obtained and analyzed. Only those participants with data available at specified time points were analyzed (represented as n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat 2 mg</title>
            <description>Participants received daprodustat tablets 2 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O2">
            <title>Daprodustat 4 mg</title>
            <description>Participants received daprodustat tablets 4 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O3">
            <title>Daprodustat 8 mg</title>
            <description>Participants received daprodustat tablets 8 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O4">
            <title>Daprodustat 12 mg</title>
            <description>Participants received daprodustat tablets 12 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O5">
            <title>Daprodustat 16 mg</title>
            <description>Participants received daprodustat tablets 16 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O6">
            <title>Daprodustat 20 mg</title>
            <description>Participants received daprodustat tablets 20 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O7">
            <title>Daprodustat 24 mg</title>
            <description>Participants received daprodustat tablets 24 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O8">
            <title>Daprodustat 32 mg</title>
            <description>Participants received daprodustat tablets 32 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O9">
            <title>Daprodustat 48 mg</title>
            <description>Participants received daprodustat tablets 48 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Trough Concentration (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13).</description>
          <population>Pharmacokinetic Population comprised of all randomized participants for whom a post-Baseline pharmacokinetic sample was obtained and analyzed. Only those participants with data available at specified time points were analyzed (represented as n=X in the category titles).</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daprodustat; n=1, 2, 10, 18, 14, 9, 6, 3, 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2400" spread="NA">NA indicates that data was not available as geometric coefficient of variation could not be calculated for single participant.</measurement>
                    <measurement group_id="O2" value="1.1207" spread="494.71"/>
                    <measurement group_id="O3" value="0.1786" spread="77.35"/>
                    <measurement group_id="O4" value="0.3727" spread="277.88"/>
                    <measurement group_id="O5" value="0.3443" spread="100.78"/>
                    <measurement group_id="O6" value="0.3871" spread="161.05"/>
                    <measurement group_id="O7" value="0.1621" spread="42.17"/>
                    <measurement group_id="O8" value="0.2768" spread="140.82"/>
                    <measurement group_id="O9" value="0.3486" spread="68.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220; n=4, 17,42, 57, 40, 25, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8623" spread="241.17"/>
                    <measurement group_id="O2" value="0.5893" spread="255.59"/>
                    <measurement group_id="O3" value="0.6341" spread="123.92"/>
                    <measurement group_id="O4" value="1.1572" spread="184.51"/>
                    <measurement group_id="O5" value="1.1654" spread="191.57"/>
                    <measurement group_id="O6" value="1.1792" spread="168.59"/>
                    <measurement group_id="O7" value="1.4987" spread="136.35"/>
                    <measurement group_id="O8" value="1.6974" spread="6.82"/>
                    <measurement group_id="O9" value="1.3531" spread="19.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818; n=1, 4, 5, 20, 14, 7, 4, 3, 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3620" spread="NA">NA indicates that data was not available as geometric coefficient of variation could not be calculated for single participant.</measurement>
                    <measurement group_id="O2" value="0.2867" spread="111.67"/>
                    <measurement group_id="O3" value="0.1594" spread="16.91"/>
                    <measurement group_id="O4" value="0.2996" spread="105.55"/>
                    <measurement group_id="O5" value="0.3027" spread="69.12"/>
                    <measurement group_id="O6" value="0.2868" spread="109.23"/>
                    <measurement group_id="O7" value="0.2585" spread="30.72"/>
                    <measurement group_id="O8" value="0.2414" spread="29.66"/>
                    <measurement group_id="O9" value="0.2111" spread="80.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102; n=4, 17, 45, 59, 43, 27, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9951" spread="122.94"/>
                    <measurement group_id="O2" value="0.8372" spread="121.27"/>
                    <measurement group_id="O3" value="0.9634" spread="95.99"/>
                    <measurement group_id="O4" value="1.5100" spread="105.50"/>
                    <measurement group_id="O5" value="1.5480" spread="122.95"/>
                    <measurement group_id="O6" value="1.6555" spread="133.94"/>
                    <measurement group_id="O7" value="3.2099" spread="67.36"/>
                    <measurement group_id="O8" value="1.6892" spread="30.44"/>
                    <measurement group_id="O9" value="1.8595" spread="48.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104; n=6, 17, 45, 59, 43, 27, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9750" spread="408.49"/>
                    <measurement group_id="O2" value="1.9588" spread="163.27"/>
                    <measurement group_id="O3" value="2.0381" spread="124.74"/>
                    <measurement group_id="O4" value="3.5141" spread="136.72"/>
                    <measurement group_id="O5" value="3.3872" spread="182.27"/>
                    <measurement group_id="O6" value="3.6000" spread="173.62"/>
                    <measurement group_id="O7" value="6.5730" spread="99.82"/>
                    <measurement group_id="O8" value="4.2068" spread="15.44"/>
                    <measurement group_id="O9" value="4.1894" spread="23.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398; n=2, 7, 22, 41, 33, 20, 15, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1778" spread="20.55"/>
                    <measurement group_id="O2" value="0.6069" spread="271.48"/>
                    <measurement group_id="O3" value="0.2362" spread="76.76"/>
                    <measurement group_id="O4" value="0.4444" spread="144.99"/>
                    <measurement group_id="O5" value="0.3917" spread="169.77"/>
                    <measurement group_id="O6" value="0.3728" spread="197.51"/>
                    <measurement group_id="O7" value="0.3992" spread="153.15"/>
                    <measurement group_id="O8" value="0.3963" spread="16.52"/>
                    <measurement group_id="O9" value="0.2280" spread="56.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401; n=6, 17, 45, 59, 44, 27, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4466" spread="190.80"/>
                    <measurement group_id="O2" value="3.5579" spread="102.68"/>
                    <measurement group_id="O3" value="4.0910" spread="148.03"/>
                    <measurement group_id="O4" value="6.8137" spread="102.34"/>
                    <measurement group_id="O5" value="5.6037" spread="130.97"/>
                    <measurement group_id="O6" value="8.4611" spread="128.74"/>
                    <measurement group_id="O7" value="11.7372" spread="65.37"/>
                    <measurement group_id="O8" value="6.0453" spread="140.63"/>
                    <measurement group_id="O9" value="16.2584" spread="41.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13).</description>
        <time_frame>Pre-dose on Day 1; Pre-dose and at 0.5, 1, 2, 3 hours post-dose on any one post-Baseline visit day between Week 8 and Week 52</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points were analyzed (represented as n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Daprodustat 2 mg</title>
            <description>Participants received daprodustat tablets 2 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O2">
            <title>Daprodustat 4 mg</title>
            <description>Participants received daprodustat tablets 4 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O3">
            <title>Daprodustat 8 mg</title>
            <description>Participants received daprodustat tablets 8 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O4">
            <title>Daprodustat 12 mg</title>
            <description>Participants received daprodustat tablets 12 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O5">
            <title>Daprodustat 16 mg</title>
            <description>Participants received daprodustat tablets 16 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O6">
            <title>Daprodustat 20 mg</title>
            <description>Participants received daprodustat tablets 20 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O7">
            <title>Daprodustat 24 mg</title>
            <description>Participants received daprodustat tablets 24 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O8">
            <title>Daprodustat 32 mg</title>
            <description>Participants received daprodustat tablets 32 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
          <group group_id="O9">
            <title>Daprodustat 48 mg</title>
            <description>Participants received daprodustat tablets 48 mg orally three-times weekly at the time of the pharmacokinetic visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13).</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points were analyzed (represented as n=X in the category titles).</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daprodustat; n=8, 20, 49, 57, 45, 28, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5832" spread="227.65"/>
                    <measurement group_id="O2" value="51.9261" spread="227.59"/>
                    <measurement group_id="O3" value="113.4049" spread="179.69"/>
                    <measurement group_id="O4" value="143.8790" spread="233.09"/>
                    <measurement group_id="O5" value="126.6824" spread="288.50"/>
                    <measurement group_id="O6" value="212.5087" spread="152.47"/>
                    <measurement group_id="O7" value="290.3163" spread="87.39"/>
                    <measurement group_id="O8" value="197.7071" spread="36.53"/>
                    <measurement group_id="O9" value="310.1938" spread="190.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2391220; n=8, 19, 50, 59, 45, 28, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6298" spread="60.93"/>
                    <measurement group_id="O2" value="4.0224" spread="134.91"/>
                    <measurement group_id="O3" value="6.3826" spread="198.78"/>
                    <measurement group_id="O4" value="8.9535" spread="126.76"/>
                    <measurement group_id="O5" value="9.5131" spread="167.92"/>
                    <measurement group_id="O6" value="11.8995" spread="172.35"/>
                    <measurement group_id="O7" value="22.3378" spread="95.60"/>
                    <measurement group_id="O8" value="9.3582" spread="71.78"/>
                    <measurement group_id="O9" value="31.6698" spread="84.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2487818; n=7, 18, 47, 56, 45, 28, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0320" spread="73.45"/>
                    <measurement group_id="O2" value="3.2703" spread="143.75"/>
                    <measurement group_id="O3" value="6.3474" spread="175.79"/>
                    <measurement group_id="O4" value="8.0134" spread="146.43"/>
                    <measurement group_id="O5" value="6.4276" spread="278.04"/>
                    <measurement group_id="O6" value="9.6617" spread="207.18"/>
                    <measurement group_id="O7" value="19.9693" spread="94.09"/>
                    <measurement group_id="O8" value="8.4327" spread="64.98"/>
                    <measurement group_id="O9" value="29.3042" spread="72.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506102; n=8, 19, 51, 59, 45, 28, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8328" spread="101.92"/>
                    <measurement group_id="O2" value="1.4018" spread="84.93"/>
                    <measurement group_id="O3" value="2.0385" spread="85.59"/>
                    <measurement group_id="O4" value="2.8357" spread="68.15"/>
                    <measurement group_id="O5" value="3.2007" spread="89.86"/>
                    <measurement group_id="O6" value="3.5712" spread="96.48"/>
                    <measurement group_id="O7" value="6.4555" spread="59.57"/>
                    <measurement group_id="O8" value="2.4981" spread="71.38"/>
                    <measurement group_id="O9" value="7.1245" spread="87.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2506104; n=8, 19, 51, 59, 45, 28, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2020" spread="81.23"/>
                    <measurement group_id="O2" value="5.2039" spread="98.70"/>
                    <measurement group_id="O3" value="7.5220" spread="131.81"/>
                    <measurement group_id="O4" value="10.8186" spread="84.31"/>
                    <measurement group_id="O5" value="11.5783" spread="130.74"/>
                    <measurement group_id="O6" value="13.8509" spread="125.27"/>
                    <measurement group_id="O7" value="24.4926" spread="84.96"/>
                    <measurement group_id="O8" value="9.5457" spread="73.58"/>
                    <measurement group_id="O9" value="30.4034" spread="79.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531398; n=8, 17, 46, 59, 45, 27, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2731" spread="57.92"/>
                    <measurement group_id="O2" value="2.3676" spread="84.23"/>
                    <measurement group_id="O3" value="3.7348" spread="131.10"/>
                    <measurement group_id="O4" value="3.8017" spread="177.36"/>
                    <measurement group_id="O5" value="4.0850" spread="209.29"/>
                    <measurement group_id="O6" value="6.1029" spread="137.40"/>
                    <measurement group_id="O7" value="10.7532" spread="98.46"/>
                    <measurement group_id="O8" value="4.6296" spread="72.00"/>
                    <measurement group_id="O9" value="14.7844" spread="81.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2531401; n=7, 19, 51, 59, 45, 28, 16, 3, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0473" spread="100.05"/>
                    <measurement group_id="O2" value="4.0012" spread="88.64"/>
                    <measurement group_id="O3" value="5.4631" spread="120.63"/>
                    <measurement group_id="O4" value="8.8488" spread="80.17"/>
                    <measurement group_id="O5" value="8.4814" spread="93.83"/>
                    <measurement group_id="O6" value="10.7368" spread="90.83"/>
                    <measurement group_id="O7" value="14.7926" spread="59.24"/>
                    <measurement group_id="O8" value="7.1458" spread="174.98"/>
                    <measurement group_id="O9" value="20.1044" spread="67.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent serious adverse events (SAEs) and non-serious adverse events (non-serious AEs) were collected up to 52 weeks.</time_frame>
      <desc>Safety Population was used to assess SAEs and non-serious AEs, which comprised of all randomized participants who have taken at least 1 dose of study treatment. One participant from Randomized (ITT) Population (N=407) did not receive study treatment, hence was not included in Safety Population (N=406).</desc>
      <group_list>
        <group group_id="E1">
          <title>Daprodustat</title>
          <description>Participants received daprodustat tablets with titrated dose levels ranging from 2, 4, 8, 12, 16, 20, 24, 32 and 48 milligrams (mg) orally three-times weekly up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 grams per deciliter [g/dL]). In order to maintain the study blind, participants also received saline intravenous (IV) injection once weekly or three-times weekly depending on dose level, up to 52 weeks as an inactive treatment for the IV formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa</title>
          <description>Participants received epoetin alfa with titrated dose levels ranging from 1500 Units to 60,000 Units total weekly dose and administered as IV injection once weekly or three-times weekly depending on dose level up to 52 weeks. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (10 to 11 g/dL). In order to maintain the study blind, participants also received placebo tablets matching to daprodustat orally three-times weekly up to 52 weeks as an inactive treatment for the tablet formulation. All participants were followed up at 4 to 6 weeks after last dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="270"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Campylobacter colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Catheter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Injection site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Prostatitis Escherichia coli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Proteus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="270"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vascular access malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vascular access site thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vascular access site pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Smooth muscle cell neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Dialysis induced hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="23" subjects_at_risk="270"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="270"/>
                <counts group_id="E2" events="21" subjects_affected="11" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="270"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="270"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="270"/>
                <counts group_id="E2" events="26" subjects_affected="13" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="35" subjects_affected="22" subjects_at_risk="270"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="270"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

